Graphic: 7 Biosimilars OK’d by FDA

The U.S. Food and Drug Administration to date has approved seven biosimilars, including Zarxio, Inflectra and Erelzi.

A rundown on the seven biosimilars can be seen at left.

(Graphic courtesy of Center for Biosimilars)

You might also be interested in:

FDA Moves on Biosimilars, Outlines New Plans December 15, 2018
Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026 August 19, 2019
Article: Mandated Prices in Drug Ads a Legal Minefield August 29, 2018
FDA Creating Roadmap for RWE Integration December 7, 2018
Article Touts RWE as Boon to Biosimilars, Special Populations September 6, 2018
FDA Gets Significant Boost to Budget February 18, 2019
FDA OKs Jacobus Pharmaceuticals' LEMS Treatment May 13, 2019